Addressing drug resistance in cancer with macromolecular chemotherapeutic agents
Drug resistance to chemotherapeutics is a recurrent issue plaguing many cancer treatment
regimens. To circumvent resistance issues, we have designed a new class of …
regimens. To circumvent resistance issues, we have designed a new class of …
[引用][C] Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents
NH Park, W Cheng, F Lai, C Yang… - Journal of the American …, 2018 - cir.nii.ac.jp
Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents.
NH Park, W Cheng, F Lai, C Yang… - Journal of the …, 2018 - europepmc.org
Drug resistance to chemotherapeutics is a recurrent issue plaguing many cancer treatment
regimens. To circumvent resistance issues, we have designed a new class of …
regimens. To circumvent resistance issues, we have designed a new class of …
Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents
NH Park, W Cheng, F Lai, C Yang, PF De Sessions… - JACS, 2018 - research.ibm.com
Drug resistance to chemotherapeutics is a recurrent issue plaguing many cancer treatment
regimens. To circumvent resistance issues, we have designed a new class of …
regimens. To circumvent resistance issues, we have designed a new class of …
Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents
NH Park, W Cheng, F Lai, C Yang… - Journal of the …, 2018 - pubmed.ncbi.nlm.nih.gov
Drug resistance to chemotherapeutics is a recurrent issue plaguing many cancer treatment
regimens. To circumvent resistance issues, we have designed a new class of …
regimens. To circumvent resistance issues, we have designed a new class of …